2013, Number 1
Rev Mex Patol Clin Med Lab 2013; 60 (1)
Antithyroglobulin autoantibodies in the determination of thyroglobulin during the follow-up of patients operated for thyroid differentiated carcinoma
Belkys S, Marrero MT, Oliva JP, Martínez AÍ, Velasco M
PDF size: 61.55 Kb.
ABSTRACTThe thyroid cancer constitutes the endocrinology neoplasia the most frequency. The human thyroglobulin is the main tumor marker during the postoperative follow-up of patients presenting with thyroid differentiated cancer. The previous premise is valid if don’t exist thyroglobulin antibodies that can interfere in its quantification, being this the analytic main problem that involve the utility of the thyroglobulin like tumor marker and that it limits its clinical utility. One hundred patients were studied assisted in the thyroid surgery of the National Institute of Oncology and Radiobiology to who you practiced total thyroidectomy to present differentiated cancer of thyroid. 83 women and 14 men were included in this study (half age of 45.1 ± 11.2 years). They were assessment the thyroglobulin levels and of thyroglobulin antibodies in serum, using for it two different methods immunometrics; Immunoradiometric method and radioimmunoassay respectively. We studied the interference that provokes the thyroglobulin antibodies in the quantification of thyroglobulin during the postoperative follow-up of patients presenting with thyroid differentiated cancer. The recovery test does not provide reliable information of the interference of antithyroglobulin autoantibodies in the determination of thyroglobulin.
For all blood samples sent to the laboratory for determination of thyroglobulin, they should also perform quantization of antithyroglobulin autoantibodies interference. With the results, a protocol should be established for monitoring patients operated for differentiated thyroid carcinoma.